1 of 1
Story summary
- Sona Nanotech Inc. reported an 80% response rate in its first-in-human study of Targeted Hyperthermia Therapy (THT) for advanced, immunotherapy-resistant cutaneous metastatic melanoma.
- The trial involved ten patients, with six achieving complete tumor clearance and two showing partial improvement within two weeks.
- CEO David Regan noted that the results exceeded expectations, prompting plans for further clinical trials in Canada.
- Safety data revealed one serious adverse event unrelated to THT, and two patients died from disease progression.
- Sona will host a webinar to discuss the findings and future plans.
